FB   234.72 (-1.19%)
GOOGL   1,483.64 (+2.89%)
AMZN   2,906.88 (+0.98%)
NVDA   387.40 (+1.63%)
CGC   16.54 (+0.43%)
MU   50.29 (+1.17%)
TSLA   1,205.01 (+7.63%)
AMD   52.40 (-0.34%)
T   30.37 (+1.54%)
F   6.10 (+1.84%)
DIS   113.34 (+0.28%)
BAC   23.52 (+1.12%)
FB   234.72 (-1.19%)
GOOGL   1,483.64 (+2.89%)
AMZN   2,906.88 (+0.98%)
NVDA   387.40 (+1.63%)
CGC   16.54 (+0.43%)
MU   50.29 (+1.17%)
TSLA   1,205.01 (+7.63%)
AMD   52.40 (-0.34%)
T   30.37 (+1.54%)
F   6.10 (+1.84%)
DIS   113.34 (+0.28%)
BAC   23.52 (+1.12%)
FB   234.72 (-1.19%)
GOOGL   1,483.64 (+2.89%)
AMZN   2,906.88 (+0.98%)
NVDA   387.40 (+1.63%)
CGC   16.54 (+0.43%)
MU   50.29 (+1.17%)
TSLA   1,205.01 (+7.63%)
AMD   52.40 (-0.34%)
T   30.37 (+1.54%)
F   6.10 (+1.84%)
DIS   113.34 (+0.28%)
BAC   23.52 (+1.12%)
FB   234.72 (-1.19%)
GOOGL   1,483.64 (+2.89%)
AMZN   2,906.88 (+0.98%)
NVDA   387.40 (+1.63%)
CGC   16.54 (+0.43%)
MU   50.29 (+1.17%)
TSLA   1,205.01 (+7.63%)
AMD   52.40 (-0.34%)
T   30.37 (+1.54%)
F   6.10 (+1.84%)
DIS   113.34 (+0.28%)
BAC   23.52 (+1.12%)
Log in

NYSE:HAEHaemonetics Stock Price, Forecast & News

$92.35
+2.67 (+2.98 %)
(As of 07/2/2020 02:38 PM ET)
Add
Compare
Today's Range
$90.18
Now: $92.35
$92.56
50-Day Range
$84.96
MA: $97.29
$110.58
52-Week Range
$63.41
Now: $92.35
$140.36
Volume11,510 shs
Average Volume1.08 million shs
Market Capitalization$4.65 billion
P/E Ratio62.82
Dividend YieldN/A
Beta0.69
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.
Read More
Haemonetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
CUSIP40502410
Phone781-848-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$988.48 million
Cash Flow$5.77 per share
Book Value$11.67 per share

Profitability

Net Income$76.53 million

Miscellaneous

Employees3,004
Market Cap$4.65 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.

Haemonetics (NYSE:HAE) Frequently Asked Questions

How has Haemonetics' stock been impacted by COVID-19 (Coronavirus)?

Haemonetics' stock was trading at $103.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HAE shares have decreased by 11.0% and is now trading at $92.32. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Haemonetics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Haemonetics.

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Haemonetics.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) released its quarterly earnings results on Tuesday, May, 5th. The medical instruments supplier reported $0.69 EPS for the quarter, missing analysts' consensus estimates of $0.73 by $0.04. The medical instruments supplier had revenue of $238.50 million for the quarter, compared to the consensus estimate of $246.53 million. Haemonetics had a net margin of 7.74% and a return on equity of 29.33%. The company's revenue for the quarter was down 4.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.61 EPS. View Haemonetics' earnings history.

What price target have analysts set for HAE?

7 analysts have issued 1-year target prices for Haemonetics' stock. Their forecasts range from $113.00 to $145.00. On average, they anticipate Haemonetics' share price to reach $134.83 in the next twelve months. This suggests a possible upside of 46.0% from the stock's current price. View analysts' price targets for Haemonetics.

Has Haemonetics been receiving favorable news coverage?

Media coverage about HAE stock has trended very negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Haemonetics earned a news impact score of -3.3 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Haemonetics.

Are investors shorting Haemonetics?

Haemonetics saw a increase in short interest in June. As of June 15th, there was short interest totaling 1,420,000 shares, an increase of 12.7% from the May 31st total of 1,260,000 shares. Based on an average daily volume of 580,400 shares, the short-interest ratio is presently 2.4 days. Approximately 2.9% of the company's shares are short sold. View Haemonetics' Current Options Chain.

Who are some of Haemonetics' key competitors?

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include Endologix (ELGX), Chipotle Mexican Grill (CMG), Zoetis (ZTS), Align Technology (ALGN), Netflix (NFLX), NVIDIA (NVDA), Citigroup (C), Johnson & Johnson (JNJ), Micron Technology (MU) and Pfizer (PFE).

Who are Haemonetics' key executives?

Haemonetics' management team includes the following people:
  • Mr. Christopher Simon, CEO, Pres & Director (Age 55)
  • Mr. William P. Burke, CFO & Exec. VP
  • Ms. Michelle L. Basil, Exec. VP, Gen. Counsel & Sec.
  • Ms. Jacqueline D. Scanlan, Sr. VP of Global HR
  • Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 42)

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $92.32.

How big of a company is Haemonetics?

Haemonetics has a market capitalization of $4.64 billion and generates $988.48 million in revenue each year. The medical instruments supplier earns $76.53 million in net income (profit) each year or $3.31 on an earnings per share basis. Haemonetics employs 3,004 workers across the globe.

What is Haemonetics' official website?

The official website for Haemonetics is www.haemonetics.com.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.